T3X Stock Overview
A commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Telix Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$12.51 |
| 52 Week High | AU$12.80 |
| 52 Week Low | AU$9.60 |
| Beta | 2.4 |
| 11 Month Change | 5.04% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 4.16% |
Recent News & Updates
Recent updates
Shareholder Returns
| T3X | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 3.6% | 2.6% | 4.5% |
| 1Y | n/a | -16.4% | 13.4% |
Return vs Industry: Insufficient data to determine how T3X performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how T3X performed against the German Market.
Price Volatility
| T3X volatility | |
|---|---|
| T3X Average Weekly Movement | 13.4% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: T3X has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine T3X's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 423 | Chris Behrenbruch | telixpharma.com |
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma.
Telix Pharmaceuticals Limited Fundamentals Summary
| T3X fundamental statistics | |
|---|---|
| Market cap | €4.22b |
| Earnings (TTM) | €30.32m |
| Revenue (TTM) | €398.07m |
139.1x
P/E Ratio10.6x
P/S RatioIs T3X overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| T3X income statement (TTM) | |
|---|---|
| Revenue | AU$645.68m |
| Cost of Revenue | AU$240.33m |
| Gross Profit | AU$405.35m |
| Other Expenses | AU$356.16m |
| Earnings | AU$49.19m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.15 |
| Gross Margin | 62.78% |
| Net Profit Margin | 7.62% |
| Debt/Equity Ratio | 2.9% |
How did T3X perform over the long term?
See historical performance and comparison